Fennec's revenue nearly tripled from $7.0M in 2024Q3 to $17.9M in 2026Q2 (85.2% YoY growth), producing a first sustained operating profit of $1.7M (9.7% operating margin) since the anomalous 2024Q1 milestone quarter, while zero debt and $41.2M of cash suggest ...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | $0.05+150.0% vs $0.02 | $18M+10.3% vs $16M |
Q2 2026 May 14, 2026 | $0.01+150.0% vs -$0.02 | $15M+8.6% vs $14M |
Q2 2026 Mar 24, 2026 | -$0.17-666.7% vs $0.03 | $14M-6.5% vs $15M |
Q4 2025 Nov 13, 2025 | -$0.02+75.0% vs -$0.08 | $12M-15.2% vs $15M |
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has earned an average rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The
Adherex Technologies (NASDAQ: FENC - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Analyst Recommendations This is a summary of recent
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Benchmark FENC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Fennec Pharmaceuticals Inc. (FENC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.08 | $350.15M | -28.00 | -6.09% | -21.82% | -66.77% | — | |
| $1.00 | $249.3M | -3.57 | 53.24% | -246.58% | -73.05% | — | |
| $1.11 | $1.87M | -0.59 | 36.68% | -10.33% | -53.56% | — | |
| $125.63 | $14.9B | 49.07 | 37.55% | 24.86% | 180.63% | — | |
| $40.70 | $2.36B | -59.85 | 8.63% | -13.23% | -10.42% | — | |
| $60.59 | $5.03B | 7.79 | 114.51% | -3.8% | — | — |
Fennec Pharmaceuticals Inc. (FENC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Fennec Pharmaceuticals Inc. (FENC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 10, 2026·SEC
May 22, 2026·SEC
May 18, 2026·SEC
Get notified when FENC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Fennec Pharmaceuticals Inc. (FENC) stock FAQ — growth, dividends, profitability & financials explained
Fennec Pharmaceuticals Inc. (FENC) reported $59.2M in revenue for fiscal year 2025.
Fennec Pharmaceuticals Inc. (FENC) saw revenue decline by 6.1% over the past year.
Fennec Pharmaceuticals Inc. (FENC) reported a net loss of $3.3M for fiscal year 2025.
Fennec Pharmaceuticals Inc. (FENC) has a return on equity (ROE) of -66.8%. Negative ROE indicates the company is unprofitable.
Fennec Pharmaceuticals Inc. (FENC) had negative free cash flow of $2.0M in fiscal year 2025, likely due to heavy capital investments.
